心泰醫療(02291.HK)公佈中期業績:純利同比飆升213.73% 毛利率增至88.9%
格隆匯8月22日丨心泰醫療(02291.HK)公佈中期業績,公司業務板塊整體發展勢頭良好,實現了收入的穩定增長。截至2023年6月30日止六個月,公司收益為人民幣1.66億元,同比增長32.96%;公司股東應占期內盈利為為人民幣7609.4萬元,同比增長213.73%;基本每股盈利為人民幣0.22元。
毛利由截至2022年6月30日止六個月的人民幣1.095億元增加34.8%至截至2023年6月30日止六個月的人民幣1.475億元。毛利的增加與整體收入增長相符。截至2022年及2023年6月30日止六個月,毛利率由87.7%增長至88.9%,這主要歸因於截至2023年6月30日止六個月內毛利較高的氧化膜封堵器及全降解封堵器產品銷量增加,整體拉高了毛利率。
截至公吿日期,共計擁有20款已上市封堵器及配件產品,八款註冊審評及註冊準備中產品,另有27款處於不同研發階段的封堵器、心臟瓣膜及手術配件、機械循環輔助等在研產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.